OMED has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OMED has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. OncoMed Pharmaceuticals's interest income for the three months ended in Dec. 2018 was $0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2018 was $0.00 Mil.
The historical data trend for OncoMed Pharmaceuticals's Interest Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoMed Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | ||||||||||
Interest Income | Get a 7-Day Free Trial | - | - | - | - | - |
OncoMed Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | |
Interest Income | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.
Interest Income for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perry A Karsen | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Jack W Lasersohn | director | 18 BANK STREET, SUMMIT NJ 07901 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
Michael S Wyzga | director | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139 |
Rick E Winningham | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Denise Scots-knight | director | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139 |
Sunil Patel | officer: See Remarks | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
Paul J Hastings | officer: Chairman & CEO | 61 HARTFORD STREET, SAN FRANCISCO CA 94114 |
Laurence Lasky | director | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Jakob Dupont | officer: SVP & Chief Medical Officer | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Terry P Gould | director | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Usvp Entrepreneur Partners Viii A L P | 10 percent owner | P O BOX 7460, MENLO PARK CA 94026 |
Usvp Entrepreneur Partners Viii B L P | 10 percent owner | P O BOX 7460, MENLO PARK CA 94026 |
Usvp Viii Affiliates Fund L P | 10 percent owner | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
From GuruFocus
By Marketwired Marketwired • 08-29-2018
By Marketwired Marketwired • 04-18-2019
By GlobeNewswire GlobeNewswire • 10-20-2018
By Marketwired Marketwired • 05-01-2018
By Marketwired Marketwired • 12-05-2018
By Marketwired Marketwired • 09-24-2018
By Marketwired Marketwired • 08-02-2018
By Marketwired Marketwired • 04-23-2019
By Marketwired Marketwired • 10-20-2018
By reports.droy reports.droy • 01-29-2015
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.